Loss of DOCK2 potentiates Inflammatory Bowel Disease–associated colorectal cancer via immune dysfunction and IFNγ induction of IDO1 expression
In this paper we identify Dock2 as an immune regulator in IBD-CRC, with potential therapeutic opportunity in this area of unmet clinical need.
